MicroRNA Expression and Response to Sorafenib, Cytarabine, and Idarubicin in Patients with Acute Myeloid Leukemia

被引：0
|
作者：
Powers, M. P.
Rushton, J. R.
Yao, H.
Barkoh, B. A.
Jones, D.
Luthra, R.
机构：
[1] BCM, Houston, TX USA
[2] MDACC, Houston, TX USA
来源：
MODERN PATHOLOGY | 2010年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
1904
引用
收藏
页码：427A / 427A
页数：1
相关论文
共 50 条
  • [31] Etoposide and mitoxantrone in newly diagnosed acute myeloid leukemia patients with persistent leukemia after a course of induction therapy with cytarabine and idarubicin
    McHayleh, W. M.
    Redner, R.
    Sehgal, R.
    Raptis, A.
    Agha, M.
    Natale, J.
    Luong, T.
    Schlesselman, J. J.
    Foon, K.
    Boyiadzis, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [32] A Randomized Phase 2 Study of Idarubicin and Cytarabine With Clofarabine or Fludarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia
    Jabbour, Elias
    Short, Nicholas J.
    Ravandi, Farhad
    Huang, Xuelin
    Xiao, Lianchun
    Garcia-Manero, Guillermo
    Plunkett, William
    Gandhi, Varsha
    Sasaki, Koji
    Pemmaraju, Naveen
    Daver, Naval G.
    Borthakur, Gautam
    Jain, Nitin
    Konopleva, Marina
    Estrov, Zeev
    Kadia, Tapan M.
    Wierda, William G.
    DiNardo, Courtney D.
    Brandt, Mark
    O'Brien, Susan M.
    Cortes, Jorge E.
    Kantarjian, Hagop
    CANCER, 2017, 123 (22) : 4430 - 4439
  • [33] Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia
    Alvarado, Y
    Tsimberidou, A
    Kantarjian, H
    Cortes, J
    Garcia-Manero, G
    Faderl, S
    Thomas, D
    Estey, E
    Giles, FJ
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2003, 51 (01) : 87 - 90
  • [34] Idarubicin, high-dose cytarabine and etoposide for induction of remission in acute myeloid leukemia.
    Singhal, S
    Powles, R
    Treleaven, J
    Horton, C
    Hamblin, M
    Zomas, A
    Prendiville, J
    Saso, R
    Mackay, H
    Milan, S
    Mehta, J
    BLOOD, 1995, 86 (10) : 2039 - 2039
  • [35] A PERSONALIZED MEDICINE EX VIVO TEST TO PREDICT CLINICAL RESPONSE TO FIRST LINE INDUCTION THERAPY WITH IDARUBICIN AND CYTARABINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
    Montesinos, P.
    Cuadron, D.
    Lopez, J.
    Boyero, R.
    de Oteyza, J.
    Fernandez, P.
    Serrano, J.
    Fernandez, A.
    Herrera, P.
    Alonso
    Gonzalez, A.
    Bethancourt, C.
    Lavilla, E.
    Antonio Vera, J.
    Navas, B.
    Rodriguez, G.
    Lopez, J.
    de laguna, S. Jimenez B.
    Simiele, A.
    Gonzalez, B.
    Hernandez Rivas, J.
    Mascunano, R.
    Rayon, C.
    Burgaleta, C.
    Sierra, J.
    Janda, Al
    Troconiz, I.
    Bosanquet, A.
    Primo, D.
    Hernandez-Campo, P.
    Gorrochategui, J.
    Bennett, T.
    Liebana, B.
    Nobell, J.
    Moscardo, F.
    Sanz, M.
    HAEMATOLOGICA, 2013, 98 : 258 - 258
  • [36] A phase II comparative study of idarubicin plus cytarabine versus daunorubicin plus cytarabine in adult acute myeloid leukemia
    Masaoka, T
    Ogawa, M
    Yamada, K
    Kimura, K
    Ohashi, Y
    SEMINARS IN HEMATOLOGY, 1996, 33 (04) : 12 - 17
  • [37] Cladribine, Idarubicin, Cytarabine (araC), and Venetoclax in Treating Patients with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
    Reville, Patrick K.
    Kantarjian, Hagop M.
    Borthakur, Gautam
    Yilmaz, Musa
    Montalban-Bravo, Guillermo
    DiNardo, Courtney D.
    Andreeff, Michael
    Daver, Naval
    Jain, Nitin
    Kornblau, Steven M.
    Jabbour, Elias
    Short, Nicholas J.
    Alvarado, Yesid
    Ohanian, Maro
    Bose, Prithviraj
    Masarova, Lucia
    Wang, Sa A.
    Tidwell, Rebecca S. S.
    Estrov, Zeev E.
    Garcia-Manero, Guillermo
    Konopleva, Marina
    Ravandi, Farhad
    Kadia, Tapan M.
    BLOOD, 2020, 136
  • [38] Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: the BGMT 95 trial results
    Pigneux, Arnaud
    Perreau, Virginie
    Jourdan, Eric
    Vey, Norbert
    Dastugue, Nicole
    Huguet, Francoise
    Sotto, Jean-Jacques
    Salmi, L. Rachid
    Ifrah, Norbert
    Reiffers, Josy
    HAEMATOLOGICA, 2007, 92 (10) : 1327 - 1334
  • [39] Phase 2 Study of Combination of Cytarabine, Idarubicin, and Nivolumab for Initial Therapy of Patients with Newly Diagnosed Acute Myeloid Leukemia
    Ravandi, Farhad
    Daver, Naval
    Garcia-Manero, Guillermo
    Benton, Christopher B.
    Thompson, Philip A.
    Borthakur, Gautam
    Kadia, Tapan
    Boddu, Prajwal C.
    Alvarado, Yesid
    Jabbour, Elias J.
    Konopleva, Marina
    Takahashi, Koichi
    Kornblau, Steven
    DiNardo, Courtney D.
    Estrov, Zeev
    Flores, Wilmer
    Basu, Sreyashi
    Allison, James
    Sharma, Padmanee
    Pierce, Sherry
    Brandt, Mark
    Pike, Allison
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    BLOOD, 2017, 130
  • [40] Phase I dose escalating trial of bortezomib (Veleade®) in combination with idarubicin and cytarabine in patients with acute myeloid leukemia.
    Attar, EC
    DeAngelo, DJ
    Ballen, KK
    Learner, E
    Trehu, EG
    Schenkein, DP
    Levine, JD
    Stone, RM
    Amrein, PC
    BLOOD, 2004, 104 (11) : 498A - 499A
12345